ProQR Therapeutics (PRQR) Debt to Equity (2021 - 2024)
Historic Debt to Equity for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $0.05.
- ProQR Therapeutics' Debt to Equity fell 5010.54% to $0.05 in Q4 2024 from the same period last year, while for Dec 2024 it was $0.05, marking a year-over-year decrease of 5010.54%. This contributed to the annual value of $0.05 for FY2024, which is 5010.54% down from last year.
- Per ProQR Therapeutics' latest filing, its Debt to Equity stood at $0.05 for Q4 2024, which was down 5010.54% from $0.1 recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Debt to Equity registered a high of $0.39 during Q4 2021, and its lowest value of $0.05 during Q4 2024.
- Its 4-year average for Debt to Equity is $0.16, with a median of $0.1 in 2022.
- As far as peak fluctuations go, ProQR Therapeutics' Debt to Equity tumbled by 7371.95% in 2022, and later soared by 212.07% in 2023.
- Over the past 4 years, ProQR Therapeutics' Debt to Equity (Quarter) stood at $0.39 in 2021, then plummeted by 73.72% to $0.1 in 2022, then increased by 2.12% to $0.1 in 2023, then tumbled by 50.11% to $0.05 in 2024.
- Its Debt to Equity was $0.05 in Q4 2024, compared to $0.1 in Q4 2023 and $0.1 in Q4 2022.